The Value of Low Dose Oral Tranexamic Acid in the Treatment of A Sample of Iraqi Patients with Melisma Swadi Asmaa AbdulJaleel1, Jabur Akeel Hamed2 1Lecturer, Ph. D Pharmacology and Therapeutics, Department of Pharmacology, College of Medicine, University of Al-Qadisiyah 2Lecturer, Dermatology specialist, Department of Medicine, College of Medicine, University of AL-Qadisiyah Online published on 27 November, 2019. Abstract The aim of the present study was to evaluate the role of oral tranexamic acid in the treatment of a sample of Iraqi patients with melasma. The present study included a cohort of 20 patients with melasma with an age range of 19 to 38 years. Those patients were randomly selected from the pool of patients visiting the dermatology department at Al-Diwaniyah teaching hospital in Al-Diwaniyah province, Mid-Euphrates region of Iraq. The study started on January 2nd 2019 and extended to May 15th 2019. Patients were diagnosed by dermatology specialist and received a low dose (500 mg) of tranexamic acid orally for three months period. Response to treatment was evaluated and scored as satisfaction, partial satisfaction or no response. Satisfaction was seen in 12 patients (60.0%), whereas, partial satisfaction was seen in 5 patients (25.0%). Three patients (15.0%) have failed to respond to treatment. Response to treatment was not significantly correlated to any of the demographic characteristics of the study sample (P > 0.05) based on the findings of this study and previous reports, tranexamic acid appears to be safe and efficient mode of therapy in patients with melasma with negligible side effects if ever. Top Keywords Tranexamic acid, melasma, Iraq. Top |